# Phio Pharmaceuticals Corp. (PHIO)

> Source: Nexqual · https://nexqual.com/PHIO · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Phio Pharmaceuticals Corp. (PHIO), nexqual.com/PHIO" · informational, not investment advice.

**Price:** USD 0.85 (-2.30% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0.87 · day 0.85–0.9 · 52w 0.81–4.19 · market cap $9.9M · NCM

## Key facts
- Insider open-market purchases, last ~7 months: 7 Form 4 filings, $69K; 0 by opportunistic insiders, 3 by routine insiders.
- Total return with dividends: 1Y -59.8% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$13.5M | -$11.5M | -$10.8M | -$7.4M | -$9.2M | -$13.5M |
| Net income | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M | -$12.9M |
| EPS (diluted) | -$111.87 | -$90.90 | -$46.76 | -$9.08 | — | — |
| Free cash flow | -$11.9M | -$12.3M | -$10.8M | -$7.1M | -$8.0M | -$12.2M |
| Cash + short-term investments | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.8x · FCF yield -123.29% · Earnings yield -130.31%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
7 purchases, $69K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-28…2026-09-29 | Plott Ronald Todd | Director | 10,000 | $10K | 1.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-24 | Bradford Patricia A | Director | 6,500 | $7K | 1.01 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-22 | Bitterman Robert J | Chairman, Pres. & CEO | 2,000 | $2K | 1.03 | Routine (bought in Jun each year 2023–2025; this trade is outside those months) |
| 2026-09-15 | Bradford Patricia A | Director | 12,000 | $12K | 1.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-19 | Plott Ronald Todd | Director | 15,000 | $17K | 1.14 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Bitterman Robert J | Chairman, Pres. & CEO | 10,000 | $11K | 1.06 | Routine (bought in Jun each year 2023–2025; this trade is outside those months) |
| 2026-06-26 | Bitterman Robert J | Chairman, Pres. & CEO | 10,000 | $10K | 0.99 | Routine (bought in Jun each year 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-26 | HC Wainwright & Co. | Reiterated | Buy | $14 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -59.8% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -59.9% | -65.8% |
| Volatility (annualized) | 77.8% | 108.2% |
| Max drawdown | -60.6% (Oct 2025→Oct 2026) | -99.7% (Apr 2022→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/PHIO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-06)

- "The Company continues to focus its resources on advancing PH-762 while prudently managing general and administrative expenses and expects its existing cash and cash equivalents to fund planned operations into the second half of 2027."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.36 | $-0.33 | +10.8% | $0 | 2 |
| Next quarter (ends 2026-12-31) | $-0.39 | $-0.35 | +10.0% | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-1.45 | $-1.38 | +5.1% | $0 | 2 |
| Next fiscal year (ends 2027-12-31) | $-0.61 | $-0.86 | -29.1% | $0 | 2 |